🆕 phase III data in cisplatin-ineligible #MIBC:
Perioperative enfortumab vedotin + pembrolizumab improved outcomes vs surgery alone.
📊 pCR: 57.1% vs 8.6%
📈 Improved EFS & OS
⚠️ More grade ≥3 AEs
🩺 Christof Vulsteke, MD, PhD (@cvulsteke) | @NEJM
🔗 https://t.co/Esmr1aDkAL
A paradigm shift in bladder Cancer Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer | New England Journal of Medicine https://t.co/nn3afWv1Of @shilpaonc@y_loriot
In cisplatin-ineligible patients with muscle-invasive bladder cancer, enfortumab vedotin–pembrolizumab plus surgery led to better event-free survival (74.7%, vs. 39.4%) and overall survival (79.7%, vs. 63.1%) than surgery alone at 2 years. Full phase 3 KEYNOTE-905/EV-303 trial results: https://t.co/6M3xhml0ou
Editorial: Enfortumab Vedotin plus Pembrolizumab as Perioperative Therapy https://t.co/3uNr9TUukQ
EV/Pembro has another positive trial (EFS & OS) in MIBC. This time vs chemo/surgery rather than just surgery (KN905 (pCR 57%)). Will these results be better than NIAGARA (chemo/durva OS-0.75). In M1 disease EVP>chemo/IO, but let’s see in MIBC. https://t.co/UEV0JiMz8a
🎯 the Eurasia team are now 6-0 ahead for the Uromigos cup 🏆 @MichvdHeijden is part of the team November 7th and 8th in Nashville. Here he is in beautiful Amsterdam among the canals 🇳🇱 🇳🇱 🇳🇱 🇳🇱 🇳🇱. Hearts ♥️ points. @OncoAlert
🚨 In this episode Christof Vulsteke joins Brian and Tom to discuss his practice-changing data on neoadjuvant EVP in MIBC.
🎙️ GU Oncology Now: https://t.co/tq6ij4QLoO
🍎 Apple Podcasts: https://t.co/tq6ij4QLoO
🎧Spotify: https://t.co/Zm9En8bbMK
#ESMO25 had 4 GU trials in the Presidential plenary sessions! @myESMO
On behalf our GU team, was proud to represent @CleClinicMD for 3/4! #IMvigor011, KN-905 and PSMAddition! Truly grateful to patients & families, my co- investigators & clinical research team for helping us make meaningful contributions to these practice changing trials!
@AmandaNizamMD@ChrisWeeMD@MosheOrnsteinMD @TimGilliganMD
2/5 KN905 #ESMO25: Perioperative EVP in MIBC shows ⬆️ EFS,OS & pCR vs cystectomy alone in cisplatin ineligible MIBC. Gem/cis durvalumab showed pCR=37% & OS HR of 0.75. Will EVP be much better? Will it only apply to the cisplatin ineligible population? Will we see pembro only arm?
Witnessed the incredible energy of the @myESMO Scientific Chairs this year. @DrChoueiri & @MyriamChalabi have put together a dazzling program. Check out the #ESMO25 Presidential Session titles 👇